Li Dean Y 的 Form 4/A 修正申報
修正Recursion Pharmaceuticals, Inc.（RXRX），2021/12/9 申報
- 申報編號
- 0001209191-21-068911
- 申報時間
- 2021/12/9
- 交易日
- 2021/11/17-11/19
- 申報延遲
- 22 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2021/11/19
這份申報列了 2 筆非衍生性交易。公開市場賣出合計 $38.5 萬。交易後 22 天申報。
這份修正申報取代了 0001209191-21-065896（2021/11/19 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Li Dean YCIK 0001837016 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
- F2
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT.
- F4
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
表 I 有 1 筆交易的價格引用這則附註。